CareDx Inc logo

CareDx Inc(CDNA)

Top Performer Top performer
upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
4-STAR RATING
SELL
SELL for 2 days
PROFIT SINCE LAST BUY
+265.81% ▲
LAST CLOSE
$73.72
11/16/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for CDNA

11/16/2026: CDNA (4-star) is a SELL. SELL for 2 days. Simulated Profits (265.81%). Updated daily EoD!

CareDx Inc is a precision medicine diagnostics stock focused on non-invasive post-transplant monitoring and specialty oncology. The company's main strengths lie in its flagship molecular tests like AlloSure and its expanding profit margins supported by strong clinical adoption. Its primary growth opportunity stems from scaling new oncology offerings like NavDx and advancing pipeline programs into cell therapy. Key risks include intense competition from larger molecular diagnostics players and potential shifts in healthcare reimbursement policies. The stock best suits growth-oriented investors willing to monitor regulatory updates, reimbursement trends, and pipeline commercial execution.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitCareDx exhibits high double-digit revenue growth and expanding market opportunities in precision diagnostics.
Momentum investorStrong fit while signal remains positiveRecent earnings beats and upward earnings revisions support positive technical momentum when market upturn signals persist.
Value investorMixed fitTrading at elevated growth multiples makes it less suitable for traditional deep-value strategies.
Dividend investorWeak fitThe company does not pay dividends, focusing entirely on capital appreciation and business expansion.
Low-risk investorWeak fitHealthcare regulatory risks, litigation exposure, and stock price volatility present higher risk profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighBiotech and diagnostics stocks frequently experience sharp swings based on clinical updates or earnings reports.
Valuation riskMedium / highHigher earnings multiples require sustained execution to justify current valuation levels.
Competition risk (Natera and molecular diagnostics peers)HighIntense rivalry in non-invasive testing can pressure market share and test pricing.
Business qualityMedium / highProprietary testing technologies provide high gross margins and strong clinical moats.
Dividend incomeLow / noneNo dividend payout is provided for income-seeking investors.
Execution riskMediumSuccessful commercial rollout of new pipeline diagnostics like AlloHeme is critical for future growth.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.09B USD
Price to earnings Ratio 32.86
1Y Target Price 94.43
Price to earnings Ratio 32.86
1Y Target Price 94.43
Volume (30-day avg) 1.4M shares
Beta 2.49
52 Weeks Range 15.22 - 90.87
Updated Date 11/15/2026
52 Weeks Range 15.22 - 90.87
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 2.37

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
63.9%
Active BUY / eligible
69 / 108
30-Day BUY Count Change
+31
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Diagnostics & Research

BUY participation
61.5%
Active BUY / eligible
8 / 13
30-Day BUY Count Change
-1

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 162.36%
Avg. Invested days 51
Today’s Advisory SELL
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 5.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/16/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
CDNA receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by soft unit economics.

Company Fundamentals

★★★★★
CDNA has moderate overall fundamentals (3 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, solid cash generation (FCF margin 9.5%) and solid revenue growth (+13.8%) are partially offset by negative earnings growth (-140.6%), weak profitability (net margin -5.6%), modest insider ownership of 3.21%.

Financial Health Rating

★★★★★
CDNA's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 40.5%). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is CDNA's strongest growth driver at +14.4% FY2025 versus FY2024 (solid, 4 stars). By comparison, revenue growth (+13.8%, solid) is also solid, while earnings growth (-140.6%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 102.3% and approximately 96.7% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 3.21% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 9.16%
State Street Corp 4.70%
Vanguard Capital Management, LLC 4.18%
Deerfield Management Co 3.80%
ARK Investment Management LLC 3.72%

Unit Economics (Per $1K Revenue)

★★★★★
CDNA generates approximately $676 of gross profit, $-66 of operating income, and $95 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses explain the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -1.29% (Tax Credit)

Quantitative Style Profile

★★★★★
CDNA has a liquid profile. Valuation that is moderately attractive rather than deeply discounted is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

High VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Testing ServicesCommercial laboratory testing fees for AlloSure, AlloMap, and NavDx diagnostics.This is the primary engine driving the vast majority of company revenues.
Patient and Digital SolutionsCareDx Pharmacy services, digital health tools, and patient support infrastructure.Provides supplementary high-margin recurring engagement across transplant workflows.
Geographic ExposurePrimarily the United States healthcare market.The business is centrally concentrated on domestic hospital and transplant center networks.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-29
When After Market
Estimate 0.07
Actual 0.7

Profitability

Profit Margin 25.86%
Operating Margin (TTM) 1.57%

Management Effectiveness

Return on Assets (TTM) 0.91%
Return on Equity (TTM) 33.04%

Valuation

Trailing PE 32.86
Forward PE 68.49
Enterprise Value 3.87B
Price to Sales(TTM) 8.23
Enterprise Value 3.87B
Price to Sales(TTM) 8.23
Enterprise Value to Revenue 7.78
Enterprise Value to EBITDA 139.16
Shares Outstanding 52.54M
Shares Floating 50.80M
Shares Outstanding 52.54M
Shares Floating 50.80M
Percent Insiders 3.21
Percent Institutions 102.32

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.